Orelabrutinib (ICP-022)

DRUG2 trials

Sponsors

Beijing InnoCare Pharma Tech Co., Ltd., Second Affiliated Hospital, School of Medicine, Zhejiang University

Conditions

Marginal Zone Lymphoma of Ocular AdnexalMarginal Zone Lymphoma(MZL)Part 1：r/r B-cell MalignanciesPart 2：B-cell Malignancies

Phase 1

A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

Beijing InnoCare Pharma Tech Co., Ltd.Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies

Start: 2019-11-18End: 2025-01-30Target: 81Updated: 2023-04-18

Phase 2

Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma

Active, not recruitingNCT07247383

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityMarginal Zone Lymphoma(MZL), Marginal Zone Lymphoma of Ocular Adnexal

Start: 2025-09-19End: 2028-12-31Target: 39Updated: 2025-11-25